Skip to Content

IL-17i – A New Direction in Treating Psoriatic Arthritis Patients with Multiple Comorbidities?

Many psoriatic arthritis (PsA) patients have comorbidities, and previous treatment with TNF-alpha inhibitors (TNFi) is less effective for them than PsA without comorbidities. A new study from the Parker Institute in Copenhagen has investigated whether this also applies to PsA patients receiving their first IL-17 inhibitor (IL-17i) treatment.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top